International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

An overview on rare fungal infection “Mucormycosis” incited by covid-19

Ankit Agrawal, Sourabh Jain, Shikha Sharma, Abhimanyu S Rathore, Arun K Gupta

Associate Professor, Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India; Chameli Devi Institute of Pharmacy, Indore, Madhya Pradesh, India

Article Information

Volume / Issue2 / 3 (July-September 2021)
Pages24-26
AccessOpen Access

Publication Timeline

  • Received20 July 2021
  • Accepted10 August 2021

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

India is now seeing in COVID-19-induced Mucormycosis or “black fungus” cases in many regions, despite still grappling with second wave of coronavirus infections. Mucormycosis, also known as black fungus, is a severe but rare fungal infection caused by the mucormycetes, a group of moulds. It usually affects those with health problems or who are taking drugs that limit the body’s ability to combat germs and illness. The resurgence in black fungus infections may be attributed to the use of steroids in the management of COVID infection, as well as the fact that many COVID patients had diabetes as co-morbidity. Despite its occurrence since the beginning of the pandemic, there are still unanswered concerns regarding the origin of this fungal infection. The existing report of black fungus morbidity during the latest COVID-19 crisis in this study is early detection of this potentially life-threatening illness and timely care was critical in lowering mortality rates.

Keywords

COVID-19MucormycosisBlack FungusAntifungal

References

  1. Hejazi II, Beg MA, Imam MA, et al. Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV- 2 main protease. Food Chem Toxicol. 2021; 150:112057. [Google Scholar][Crossref]
  2. Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi (Basel). 2019; 5(1):26. [Google Scholar][Crossref]
  3. Francis JR, Villanueva P, Bryant P, et al. Mucormycosis in Children: Review and Recommendations for Management. J Pediatric Infect Dis Soc. 2018; 7(2):159-164. [Google Scholar][Crossref]
  4. Afroze SN, Korlepara R, Rao GV, et al. Mucormycosis in a Diabetic Patient: A Case Report with an Insight into Its Pathophysiology. Contemp Clin Dent. 2017; 8(4):662-666. [Google Scholar][Crossref]
  5. Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: review of 174 reported cases. BMC Infect Dis. 2017; 17(1):283. [Google Scholar][Crossref]
  6. Kanamori H, Rutala WA, Sickbert-Bennett EE, et al. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015; 61(3):433-444. [Google Scholar][Crossref]
  7. Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis. 2012; 54 (1):S16-S22. [Google Scholar][Crossref]
  8. Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012; 54 (1):S23-S34. [Google Scholar][Crossref]
  9. Spellberg B. Gastrointestinal mucormycosis: an evolving disease. Gastroenterol Hepatol (N Y). 2012; 8(2):140-142. [Google Scholar][Crossref]
  10. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. Clin Microbiol Infect. 2009; 15(5):2–9. [Google Scholar][Crossref]
  11. Al-Ajam MR, Bizri AR, Mokhbat J, et al. Mucormycosis in the Eastern Mediterranean: a seasonal disease. Epidemiol Infect. 2006; 134(2):341- 346. [Google Scholar][Crossref]
  12. Ahmed A, Adelmann D, Fahal A, et al. Environmental occurrence of Madurella mycetomatis the major agent of human eumycetoma in Sudan. J Clin Microbiol. 2002; 40(3):1031-1036. [Google Scholar][Crossref]
  13. Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000; 13(2):236-301. [Google Scholar][Crossref]

How to Cite

Agrawal, A., Jain, S., Sharma, S., Rathore, A. S., & Gupta, A. K. (2021). An overview on rare fungal infection “Mucormycosis” incited by covid-19. International Journal of Medical and All Body Health Research, 2(3), 24-26.

Agrawal, Ankit, et al. "An overview on rare fungal infection “Mucormycosis” incited by covid-19." International Journal of Medical and All Body Health Research, vol. 2, no. 3, 2021, pp. 24-26.

Agrawal, A., Jain, S., Sharma, S., Rathore, A. S. and Gupta, A. K. (2021) 'An overview on rare fungal infection “Mucormycosis” incited by covid-19', International Journal of Medical and All Body Health Research, 2(3), pp. 24-26.

Agrawal A, Jain S, Sharma S, Rathore AS, Gupta AK. An overview on rare fungal infection “Mucormycosis” incited by covid-19. International Journal of Medical and All Body Health Research. 2021;2(3):24-26.

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex ResearchGate BASE

A newly published article may take a few days to appear on these services.